ClinicalTrials.gg
Drug

Pralsetinib clinical trials

Also written Gavreto® and BLU-667.

studies test it
9
open now
3
in phase 3
2
first study started
2017

How each study uses pralsetinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the pralsetinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
4 Sept 2020 · GAVRETO · NDA 213721 (FDA, Drugs@FDA)
European Union
18 Nov 2021 · Gavreto · EMEA/H/C/005413 (EMA; now withdrawn)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Pralsetinib
8

Brand

Gavreto®
3

Development codes

BLU-667
2
RG6396
1
RO7499790
1

Studies by the year they started

9 studies that test it; most in 2020 (2)

Studies that test pralsetinib, by start year
YearStudies
20171
20202
20212
20231
20241
20251
20261

By phase

A phase 1/2 study counts in both.

Phase 1
1
Phase 2
5
Phase 3
2
Phase 4
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 7 · Other 2

Hoffmann-La Roche (4) · Genentech, Inc. (2) · Fujian Medical University (1) · Rigel Pharmaceuticals (1) · Sun Yat-sen University (1)

Often tested with

Tested in the same studies.

Alectinib (3) · Entrectinib (3) · Atezolizumab (3) · Divarasib (2) · Ipatasertib (2) · Ado-Trastuzumab Emtansine (2) · Inavolisib (2) · Dabrafenib (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3

Studies that test pralsetinib.

Studies

Open first, then newest update. How each study uses pralsetinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 9

Given beside what is tested · 3 — pralsetinib is usual care or a partner of the new treatment

Codes

What other systems call pralsetinib · ClinicalTrials.gg INT001228

  • MeSH (NLM) C000655704pralsetinibOne source ClinicalTrials.gov
  • UNII (FDA) 1WPE73O1WVPRALSETINIBConfirmed FDA, Wikidata
  • RxNorm 2394936One source FDA
  • Wikidata Q97732199pralsetinibConfirmed FDA, Wikidata
  • NCI Thesaurus C132295PralsetinibOne source FDA
  • DrugBank DB15822One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.